Detail akcie Enveric Bioscie Rg online

Business Summary: Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Enveric Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased 26% to $8.1M. Higher net loss reflects Information technology services segment loss increase of 2% to $6.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$198.21 to -$37.04.